Sequence To Scale In 7 Months | Future Fields Presents At PepTalk 2026

Bringing recombinant proteins from discovery to commercial manufacturing often requires navigating challenges related to expression, scale-up, stability, cost, and process consistency. This presentation explores an alternative production approach that uses transgenic Drosophila melanogaster to overcome common limitations associated with traditional cell-based systems.

Through real-world examples, including difficult-to-express proteins and a client project that reached commercial scale in seven months, it demonstrates how stable genetic integration, modular production, and streamlined scale-up can improve manufacturing efficiency. Learn how genetic stability, continuous biomass generation, traceability, and compatibility with established downstream purification workflows support reliable protein production while reducing development bottlenecks.

The discussion also examines how manufacturing flexibility, simplified infrastructure, and scalable operations can help organizations accelerate timelines and improve access to complex recombinant proteins.